The ordinary s NEW YORK, January 29, 2025--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape ...

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or ...

I n a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at $0.79, with a market capitalization of just $1.29 million. InvestingPro ...

Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS ...

Silexion Therapeutics (SLXN) announced positive data from orthotopic pancreatic cancer models demonstrating that subcutaneously administered ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...

PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...